arrow
M

Magnus Tobiasson

hematology and regenerative medicine
H指数:19
被引数:2,673

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

高危骨髓增生异常综合征患者(包括5q缺失)接受阿扎胞苷联合或不联合来那度胺治疗时,细胞遗传学对其预后的影响

2025-02-080
OAAI
Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms

大规模转录组分析支持基因组分类,并预测骨髓增生异常新生物对去甲基化药物的反应

BLOOD
IF23.1
2024-11-050
PRE
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes
2024-04-230
OAAI
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
2023-07-1716
OAAI
Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)
LEUKEMIA
IF13.4
2022-03-118
OAAI
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)

TP53等位基因状态对骨髓增生异常综合征基因组稳定性、临床表现和预后的影响 (第26卷,1549页,2020)

2021-05-045
OAAI
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (vol 26, pg 1549, 2020)

TP53等位基因状态对骨髓增生异常综合征基因组稳定性、临床表现和预后的影响 (第26卷,1549页,2020)

2021-02-092
OAAI
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Tp53等位基因状态对骨髓增生异常综合征基因组稳定性、临床表现和预后的影响

2020-08-03406
OAAI
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
2017-07-0197
OAAI